慢性肾脏病5期患者SLC6A2基因启动子甲基化状态的研究  

The Methylation in Promoter Region of SLC6A2 Gene in Chronic Kidney Disease(CKD) Stage 5 Patients

作　　者：蔡雅萍[1] 骆杰伟[2] 洪富源[2] 孟晓嵘[2] 黄昉萌[2] 胡丹[1] 杨笑[3] 郑星宇[2] 魏世超[4] 郭苗苗[4] 

机构地区：[1]福建中医药大学,福州350108 [2]福建医科大学省立临床医学院,福州350001 [3]福建卫生职业技术学院,福州350101 [4]福建省立医院,福州350001

出　　处：《中国中西医结合肾病杂志》2016年第11期966-969,I0002,共5页Chinese Journal of Integrated Traditional and Western Nephrology

基　　金：福建省中医药科研项目(No.wzsb201317);福建省自然科学基金资助项目(No.2013J01277)

摘　　要：目的：探讨慢性肾脏病5期（CKD5）患者去甲肾上腺素转运体基因（SLC6A2,NET）启动子甲基化状态。方法：选择CKD5期患者43例为实验组,选择体检人群45例为对照组。分段采用焦磷酸测序检测SLC6A2基因启动子Cp G岛甲基化。结果：实验组SLC6A2基因启动子区总甲基化率（211.63±53.89）%高于对照组（182.33±50.85）%（t=2.624,P=0.010）。协方差分析：控制年龄因素后,两组间SLC6A2基因启动子区总甲基化率差异仍具有统计学意义（F值=6.923,P=0.010）。Logistic回归分析：调整混杂因素后,其总甲基化率的相对危险度（OR值）为1.010（95%CI：1.001~1.019,P=0.025）。结论：去甲肾上腺素转运体基因启动子区域甲基化异常升高是CKD5期的危险因素之一,推测甲基化异常可能与CKD5期心血管疾病有关。Objective： To investigate the methylated status in promoter region of norepinephrine transporter gene（ SLC6A2）in chronic kidney disease（ CKD） stage 5 patients,in order to provide new insights in mechanism,prevention and treatment of CKD stage 5 patients. Methods： Forty- three patients with CKD stage 5 and 45 healthy cases were included in study. Pyrosequencing was applied to detect the methylation in promoter region of SLC6A2 gene,and the total methylation rate of Cp G island were calculated.Results： Single- factor analysis： There were significant differences between the total methylation rate of SLC6A2 gene promoter region（ t = 2. 624,P = 0. 010）,the total methylation rate in the experimental group（ 211. 63 ± 53. 89） % was higher than that in healthy group（ 182. 33 ± 50. 85） %. Covariance analysis： After control the age,the comparison of F values between groups was 6. 923,P =0. 010,indicating there were distinct differences between groups. Logistic regression model analysis： The relative risk（ OR value） of total methylation rate of SLC6A2 gene in promoter region was 1. 010（ 95% CI： 1. 001 ~ 1. 019,P = 0. 025） after adjustment for potential confounding factors,which showed statistically significant. Conclusion： The abnormal methylation of the promoter region of SLC6A2 gene is one of the risk factors that increase CKD stage 5. In addition,the study also speculate that the abnormal methylation may be associated with CKD stage 5 of cardiovascular disease.

关 键 词：CKD5期 高血压 去甲肾上腺素转运体 SLC6A2 DNA甲基化 

分 类 号：R692[医药卫生—泌尿科学]